Yoichi Furuya - Search Results

Year	Number of Results
2009	1
2010	2
2011	2
2012	1
2013	2
2014	6
2015	5
2017	2
2018	2
2019	3
2020	4
2021	4
2022	1

1

Fear of Influenza Resurgence amid COVID-19 Pandemic: Need for Effective Flu Vaccine Still Exists.

Wijesundara DK, Williams C, Sun W, Furuya AM, Furuya Y. Wijesundara DK, et al. Among authors: furuya y. Vaccines (Basel). 2021 Oct 18;9(10):1198. doi: 10.3390/vaccines9101198. Vaccines (Basel). 2021. PMID: 34696304 Free PMC article.

2

Detrimental impact of allergic airway disease on live attenuated influenza vaccine.

Roy S, Williams CM, Furuya Y. Roy S, et al. Among authors: furuya y. Health Sci Rep. 2021 Jul 1;4(3):e272. doi: 10.1002/hsr2.272. eCollection 2021 Sep. Health Sci Rep. 2021. PMID: 34250267 Free PMC article. No abstract available.

3

Return of inactivated whole-virus vaccine for superior efficacy.

Furuya Y. Furuya Y. Immunol Cell Biol. 2012 Jul;90(6):571-8. doi: 10.1038/icb.2011.70. Epub 2011 Aug 16. Immunol Cell Biol. 2012. PMID: 21844883 Review.

4

Host-pathogen interactions and immune evasion strategies in Francisella tularensis pathogenicity.

Steiner DJ, Furuya Y, Metzger DW. Steiner DJ, et al. Among authors: furuya y. Infect Drug Resist. 2014 Sep 18;7:239-51. doi: 10.2147/IDR.S53700. eCollection 2014. Infect Drug Resist. 2014. PMID: 25258544 Free PMC article. Review.

5

Virus-based vaccine vectors with distinct replication mechanisms differentially infect and activate dendritic cells.

Chiale C, Marchese AM, Furuya Y, Robek MD. Chiale C, et al. Among authors: furuya y. NPJ Vaccines. 2021 Nov 22;6(1):138. doi: 10.1038/s41541-021-00400-w. NPJ Vaccines. 2021. PMID: 34811393 Free PMC article.

6

Does Type I Interferon Limit Protective Neutrophil Responses during Pulmonary Francisella Tularensis Infection?

Furuya Y, Steiner D, Metzger DW. Furuya Y, et al. Front Immunol. 2014 Jul 23;5:355. doi: 10.3389/fimmu.2014.00355. eCollection 2014. Front Immunol. 2014. PMID: 25101094 Free PMC article. Review. No abstract available.

7

Impact of Pre-Existing Immunity on Live Attenuated Influenza Vaccine-Induced Cross-Protective Immunity.

Roy S, Williams CM, Pardo J, Wijesundara DK, Furuya Y. Roy S, et al. Among authors: furuya y. Vaccines (Basel). 2020 Aug 20;8(3):459. doi: 10.3390/vaccines8030459. Vaccines (Basel). 2020. PMID: 32825218 Free PMC article.

8

SARS-CoV-2 Vaccines: Inactivation by Gamma Irradiation for T and B Cell Immunity.

Mullbacher A, Pardo J, Furuya Y. Mullbacher A, et al. Among authors: furuya y. Pathogens. 2020 Nov 10;9(11):928. doi: 10.3390/pathogens9110928. Pathogens. 2020. PMID: 33182546 Free PMC article.

9

Impact of Pre-Existing Immunity to Influenza on Live-Attenuated Influenza Vaccine (LAIV) Immunogenicity.

Roy S, Williams CM, Wijesundara DK, Furuya Y. Roy S, et al. Among authors: furuya y. Vaccines (Basel). 2020 Nov 16;8(4):683. doi: 10.3390/vaccines8040683. Vaccines (Basel). 2020. PMID: 33207559 Free PMC article.

10

The Interleukin-33-Group 2 Innate Lymphoid Cell Axis Represents a Potential Adjuvant Target To Increase the Cross-Protective Efficacy of Influenza Vaccine.

Williams CM, Roy S, Califano D, McKenzie ANJ, Metzger DW, Furuya Y. Williams CM, et al. Among authors: furuya y. J Virol. 2021 Oct 27;95(22):e0059821. doi: 10.1128/JVI.00598-21. Epub 2021 Sep 1. J Virol. 2021. PMID: 34468174 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results